Immunoadsorption and Its Application for Desensitizing Incompatible Kidney Transplant Candidates Who Have a Potential Living Donor

Sébastien Maggioni, Eric Faubel, Martine Hermelin, Asma Allal, Lionel Rostaing

Abstract


Background. Plasmapheresis is widely used to remove potential deleterious antibodies from the blood. Because the volume of treated plasma is limited, plasmapheresis can be replaced by immunoadsorption (IA), a more tedious but sophisticated technique that enables treatment of larger volumes of plasma, i.e., > 4 L vs. 1.5–2 L. We have implemented in our department IA technique to replace plasmapheresis when we launched our ABO-incompatible (ABOi) and HLA-incompatible (HLAi) kidney-transplant programs with living kidney donors. In this setting, isoagglutinin titers (ABOi) or donor-specific alloantibodies (HLAi) have to be decreased drastically at pretransplant by apheresis and immunosuppression.
Methods. We designed a desensitization program based on IA, which was started in the first trimester of 2010 within the Acute Polyvalent Hemodialysis and Apheresis Unit (Toulouse University Hospital, France). We describe all the steps used to implement this IA technique. So far, we have performed > 225 IA sessions.
Results and Conclusions. The IA sessions were associated with a net body-weight gain of ~ 1 kg. Normally, IA is performed first and then hemodialysis on the same or following day; however, we were able to simultaneously perform IA with hemodialysis (tandem procedure). This tandem procedure has reduced costs. Implementation of IA has enabled the successful transplantation of 32 kidney patients.


Keywords


ABO-incompatible kidney transplantation; desensitization; hemodialysis; HLA-incompatible kidney transplantation; immunoadsorption; living kidney transplantation

Full Text:

PDF

References


Hohenstein B., Bornstein S.R., Aringer M. Immunoadsorption for connective tissue disease // Atheroscler. Suppl. — 2013. — 14(1). — 185-9. doi:10.1016/j. atherosclerosissup. 2012.10.034.

Kuhn C., Kuhn A., Markau S., Kastner U., Osten B. Effect of immunoadsorption on refractory idiopathic focal and segmental glomerulosclerosis // J. Clin. Apher. — 2006. — 21(4). — 266-70.

Agence Biomedicine. 2010. http://www.agence-biomedecine.fr/professionnels/le-programme-rein.html

Montgomery R.A., Warren D.S., Segev D.L., Zachary A.A. HLA incompatible renal transplantation // Curr. Opin. Organ Transplant. — 2012. — 17(4). — 386-392.

Vo A.A., Lukovsky M., Toyoda M. et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation // New Eng. J. Med. — 2008. — 359(3). — 242-251.

Yaich S. ABO-Incompatible kidney transplantation // Saudi J. Kidney Dis. Transplant. — 2013. — 24(3). — 463-472.

Tanabe K., Takahashi K., Sonda K. et al. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience // Transplantation. — 1998. — 65(2). — 224-228.

Toma H., Tanabe K., Tokumoto T. Long-term outcome of ABO-incompatible renal transplantation // Urol. Clin. N. Am. — 2001. — 28(4). — 769-780.

Inui M., Ishida H., Omoto K. Kidney transplantation at Tokyo Women’s Medical University // Clin. Transplant. — 2011. — 127-143.

Shishido S., Hyodo Y.Y., Aoki Y. et al. Outcomes of pediatric ABO-incompatible kidney transplantations are equivalent to ABO-compatible controls // Transplant. Proc. — 2012. — 44(1). — 214-216.

Genberg H., Kumlein G., Wennberg L., Tyden G. Isoagglutinin adsorption in ABO-incompatible transplantation // Trans. Apher. Sci. — 2010. — 43(2). — 231-235.

Zito A., Schena A., Grandaliano G. et al. Increasing relevance of donor-specific antibodies in antibody-mediated rejection // J. Nephrol. — 2013. — 26(2). — 237-242.

Montgomery R.A., Lonze B.E., King K.E. et al. Desensitization in HLA-incompatible kidney recipients and survival // New Eng. J. Med. — 2011. — 365(4). — 318-326.

Jordan S.C., Tyan D., Stablein D. et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial // J. Am. Soc. Nephrol. — 2004. — 15(12). — 3256-3262.

Immunosorba & Globaffin Fresenius Medical Care. http://www.fmc-ag.com/122.htm.

Al-Jedai A., Alsultan M., Almeshari K. et al. Cost analysis of kidney transplantation in highly sensitized recipients compared to intermittent maintenance hemodialysis // Ann. Transplant. — 2012. — 17(4). — 82-91.




DOI: https://doi.org/10.22141/2307-1257.0.1.07.2014.76546

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru